This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gaustadnes, M. Articles by Ingerslev, J. Search for Related Content PubMed PubMed Citation Articles by Gaustadnes, M. Articles by Ingerslev, J. Related Collections Genetics of cardiovascular disease

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1392.)
© 2000 American Heart Association, Inc.

Thrombosis

Familial Thrombophilia Associated With Homozygosity for the Cystathionine ß-Synthase 833TC Mutation

Mette Gaustadnes; Niels Rüdiger; Karsten Rasmussen; Jørgen Ingerslev

From the Department of Clinical Biochemistry (M.G., N.R., K.R) and the Center for Hemophilia and Thrombosis (J.I.), Skejby University Hospital, Aarhus, Denmark.

Correspondence to Jørgen Ingerslev, MD, Center for Hemophilia and Thrombosis, Department of Clinical Immunology, Skejby University Hospital, DK-8200 Aarhus N, Denmark. E-mail j-ing{at}post3.tele.dk

Abstract—Severe hyperhomocysteinemia due to cystathionine ß-synthase (CBS) deficiency is a strong risk factor for premature cardiovascular disease. Among untreated patients, 50% have suffered a thromboembolic event by 30 years of age. We report on 3 sisters with severe hyperhomocysteinemia due to homozygosity for the CBS 833TC mutation. These patients, who displayed no other known thrombophilic predisposition, had suffered single or multiple venous thrombosis before CBS deficiency was diagnosed relatively late in life. In this family, homozygosity for the 833TC mutation was associated with a mild phenotype with respect to other sequelae of CBS deficiency. Consequently, our results indicate that most cases with this genotype may remain undiagnosed. Investigated family members heterozygous for the 833TC mutation displayed normal total homocysteine in plasma (tHcy) levels, even when they were homozygous for the methylenetetrahydrofolate reductase 677CT polymorphism. The prevalence of homozygosity for the 833TC mutation has previously been estimated at no less than 1:20 500 in our population. Because a reduction of the severely elevated levels of tHcy in CBS deficiency reduces cardiovascular risk and because homozygosity for the 833TC mutation is more prevalent than previously thought, our results emphasize the importance of measuring tHcy routinely in thrombophilia screening.

Key Words: venous thrombosis • severe hyperhomocysteinemia • cystathionine ß-synthase deficiency • family history • mutation analysis

This article has been cited by other articles:

				I. J. Kullo, K. Ding, E. Boerwinkle, S. T. Turner, T. H. Mosley Jr, S. L.R. Kardia, and M. de Andrade Novel Genomic Loci Influencing Plasma Homocysteine Levels Stroke, July 1, 2006; 37(7): 1703 - 1709. [Abstract] [Full Text] [PDF]

				H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion Clin. Chem., January 1, 2004; 50(1): 3 - 32. [Abstract] [Full Text] [PDF]